Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Prognostic impact of lymphovascular invasion and C-MET overexpression in resected stage IB NSCLC

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

In Ho Kim

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

I.H. Kim1, J.H. Kang1, S.H. Hong1, I.H. Lee1, J.K. Park2, S.H. Sung2, S.J. Kim3, Y.K. Kim3, K. Lee4, T. Kim5, Y.S. Kim6, D.H. Han7, I.R. Yoo8, J. Kim9

Author affiliations

  • 1 Medical Oncology, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 2 Thoracic Surgery, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 3 Pulmonology, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 4 Pathology, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 5 Pathology, Yeouido St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 6 Radiation Oncology, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 7 Radiology, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 8 Nuclear Medicine, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 9 Medical Technology, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
More

Resources

Aim/Background

In stage IB non-small cell lung cancer (NSCLC), prognostic factor is not well known and administration of adjuvant treatment is controversial. The C-MET is known to be associated with the pathogenesis and progression of NSCLC. Our purpose was to evaluate the impact of clinicopathological characteristics and C-MET on recurrence free survival (RFS) and cancer-specific survival (CSS) in patients with stage IB NSCLC, undergoing surgical resection.

Methods

From 2005 to 2013, 115 patients who underwent complete resection with pathological stage IB were enrolled. We retrospectively reviewed clinicopathological data and performed immunohistochemistry with anti-MET monoclonal antibody in tissue microarrays. RFS and CSS were evaluated in patients depending on clinicopathological factors and C-MET status.

Results

The median age of 115 patients was 65 years (range: 32–82 years). The patients comprised of 78 men (68%) and 37 women (31%). The histological types were adenocarcinoma (n = 77), squamous cell carcinoma (n = 32), others (n = 6). Thirty four patients relapsed and twenty four died of cancer progression. On the univariate analysis, lymphovascular invasion (LVI) (P = .003) and C-MET overexpression (P = .014) were significantly associated with decreased RFS. Meanwhile, smoking (P = .029) and LVI (P = .040) were correlate with shortened CSS. C-MET overexpression (P = .130) were not associated with CSS. However, in larger tumor than median size (>3.5cm), C-MET overexpression (P = .039) had a relation with reduced CSS. In multivariate analysis, LVI (RFS: P = .017) and C-MET (RFS: P = 0.040) were negative independent prognostic factor for RFS, but not significant for CSS. Subgroup assessments according to LVI and C-MET co-positivity were performed with univariate and multivariate analyses. Co-presence of LVI and C-MET overexpression was a significant negative prognostic factor for CSS (P = .023) as well as RFS (P = .002) in resected stage IB NSCLC.

Conclusions

Our data indicates that stage IB NSCLC patients with LVI and C-MET overexpression showed poor survival outcome and adjuvant chemotherapy should be strongly recommended for these patients, especially with co-presence of LVI and C-MET overexpression.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings